6A7V image
Deposition Date 2018-07-04
Release Date 2018-10-10
Last Version Date 2023-11-22
Entry Detail
PDB ID:
6A7V
Keywords:
Title:
Crystal structure of Mycobacterium tuberculosis VapBC11 toxin-antitoxin complex
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.67 Å
R-Value Free:
0.20
R-Value Work:
0.18
R-Value Observed:
0.18
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Ribonuclease VapC11
Gene (Uniprot):vapC11
Chain IDs:A, C, E, G
Chain Length:139
Number of Molecules:4
Biological Source:Mycobacterium tuberculosis H37Rv
Polymer Type:polypeptide(L)
Molecule:Antitoxin VapB11
Gene (Uniprot):vapB11
Chain IDs:B (auth: K), D, F (auth: U), H
Chain Length:62
Number of Molecules:4
Biological Source:Mycobacterium tuberculosis H37Rv
Primary Citation
Structural, functional and biological insights into the role of Mycobacterium tuberculosis VapBC11 toxin-antitoxin system: targeting a tRNase to tackle mycobacterial adaptation.
Nucleic Acids Res. 46 11639 11655 (2018)
PMID: 30329074 DOI: 10.1093/nar/gky924

Abstact

Toxin-antitoxin (TA) systems are involved in diverse physiological processes in prokaryotes, but their exact role in Mycobacterium tuberculosis (Mtb) virulence and in vivo stress adaptation has not been extensively studied. Here, we demonstrate that the VapBC11 TA module is essential for Mtb to establish infection in guinea pigs. RNA-sequencing revealed that overexpression of VapC11 toxin results in metabolic slowdown, suggesting that modulation of the growth rate is an essential strategy for in vivo survival. Interestingly, overexpression of VapC11 resulted in the upregulation of chromosomal TA genes, suggesting the existence of highly coordinated crosstalk among TA systems. In this study, we also present the crystal structure of the VapBC11 heterooctameric complex at 1.67 Å resolution. Binding kinetic studies suggest that the binding affinities of toxin-substrate and toxin-antitoxin interactions are comparable. We used a combination of structural studies, molecular docking, mutational analysis and in vitro ribonuclease assays to enhance our understanding of the mode of substrate recognition by the VapC11 toxin. Furthermore, we have also designed peptide-based inhibitors to target VapC11 ribonuclease activity. Taken together, we propose that the structure-guided design of inhibitors against in vivo essential ribonucleases might be a novel strategy to hasten clearance of intracellular Mtb.

Legend

Protein

Chemical

Disease

Primary Citation of related structures